Page last updated: 2024-09-02

ecteinascidin 743 and interleukin-8

ecteinascidin 743 has been researched along with interleukin-8 in 2 studies

Compound Research Comparison

Studies (ecteinascidin 743)	Trials (ecteinascidin 743)	Recent Studies (post-2010) (ecteinascidin 743)	Studies (interleukin-8)	Trials (interleukin-8)	Recent Studies (post-2010) (interleukin-8)
660	102	404	23,523	1,167	9,990

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Allavena, P; Casali, PG; D'Incalci, M; Erba, E; Frapolli, R; Galmarini, CM; Germano, G; Greco, A; Gronchi, A; Grosso, F; Mantovani, A; Nebuloni, M; Pasqualini, F; Pesce, S; Pilotti, S; Sanfilippo, R; Simone, M; Tarantino, E; Tavecchio, M; Tercero, JC; Virdis, E	1
Allavena, P; Belgiovine, C; Bello, E; Beltrame, L; Craparotta, I; D'Incalci, M; Frapolli, R; Galmarini, CM; Liguori, M; Mannarino, L; Mantovani, A; Marchini, S; Paracchini, L	1

Other Studies

2 other study(ies) available for ecteinascidin 743 and interleukin-8

Article	Year
Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells. Cancer research, 2010, Mar-15, Volume: 70, Issue:6 Topics: Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Agents, Alkylating; C-Reactive Protein; Cell Cycle; Cell Death; Cell Line, Tumor; Chemokine CCL2; Dioxoles; Humans; Immunohistochemistry; Inflammation Mediators; Interleukin-6; Interleukin-8; Liposarcoma, Myxoid; Macrophages; Mice; Serum Amyloid P-Component; Tetrahydroisoquinolines; Trabectedin; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays	2010
Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models. British journal of cancer, 2017, Aug-22, Volume: 117, Issue:5 Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Carbolines; Caspase 8; Cell Adhesion; Cell Movement; Chemokine CCL2; Dioxoles; Down-Regulation; Female; Fibrosarcoma; Gene Expression; Gene Expression Profiling; Heterocyclic Compounds, 4 or More Rings; HL-60 Cells; Humans; Interleukin-8; Leukocyte Count; Macrophages; Mice; Mice, Inbred C57BL; Monocytes; Neovascularization, Pathologic; Ovarian Neoplasms; rho GTP-Binding Proteins; Tetrahydroisoquinolines; Trabectedin; Tumor Microenvironment; U937 Cells; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays	2017

Article

Year

Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells.

Cancer research, 2010, Mar-15, Volume: 70, Issue:6

Topics: Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Agents, Alkylating; C-Reactive Protein; Cell Cycle; Cell Death; Cell Line, Tumor; Chemokine CCL2; Dioxoles; Humans; Immunohistochemistry; Inflammation Mediators; Interleukin-6; Interleukin-8; Liposarcoma, Myxoid; Macrophages; Mice; Serum Amyloid P-Component; Tetrahydroisoquinolines; Trabectedin; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays

2010

Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models.

British journal of cancer, 2017, Aug-22, Volume: 117, Issue:5

Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Carbolines; Caspase 8; Cell Adhesion; Cell Movement; Chemokine CCL2; Dioxoles; Down-Regulation; Female; Fibrosarcoma; Gene Expression; Gene Expression Profiling; Heterocyclic Compounds, 4 or More Rings; HL-60 Cells; Humans; Interleukin-8; Leukocyte Count; Macrophages; Mice; Mice, Inbred C57BL; Monocytes; Neovascularization, Pathologic; Ovarian Neoplasms; rho GTP-Binding Proteins; Tetrahydroisoquinolines; Trabectedin; Tumor Microenvironment; U937 Cells; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays

2017